The Board of Pharmacy recently adopted  rulemaking  affecting the Iowa Prescription Monitoring Program (PMP). Beginning May 12, 2021, all Schedule V (CV) prescriptions will be required to be reported to the Iowa PMP. Common CV prescriptions include promethazine with codeine (Phenergan with Codeine®), atropine/diphenoxylate (Lomotil®) and pregabalin (Lyrica®), among others. The rule change also adds the non-prescription sale of codeine-containing cough suppressants (e.g., Robitussin-AC®), to the list of reportable transactions. For non-prescription reporting to the Iowa PMP, the pharmacy (or pharmacist) should be identified as both the prescriber and dispenser. Note, the rule change does NOT require additional PMP reporting of non-prescription pseudoephedrine-containing products. Non-prescription pseudoephedrine sales must continue to be reported to the electronic pseudoephedrine tracking system (PTS).

Pharmacies are encouraged to reach out to their software vendors now to ensure the pharmacy’s compliance beginning May 12, 2021. Pharmacies are also reminded that all reportable prescriptions are required to be reported within one business day of filling. The adopted rulemaking can be found HERE. Questions relating to the reporting to the PMP can be directed to